Fordyce Marshall's Form 4/A amendment
AmendedVera Therapeutics, Inc. (VERA) · filed Aug 12, 2026
- Accession no.
- 0001859453-26-000013
- Filed
- Aug 12, 2026, 6:42 PM ET
- Trade date
- Jul 7, 2026
- Filing delay
- 36 days
- Rule 10b5-1 plan
- Checked
- Original filed
- Jul 9, 2026
This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.96M. It was filed 36 days after the trade.
This amendment replaces 0001859453-26-000010 (filed Jul 9, 2026).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Fordyce MarshallCIK 0001859453 | Director, Officer (PRESIDENT AND CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | Class A Common Stock | MOption exerciseAcquired | +46,250 | $2.90 | +$133,977 | 281,494 | Direct | |
| Jul 7, 2026 | Class A Common Stock | SSaleDisposed | −1,000 | $40.78F3 | −$40,776.2 | 280,494 | Direct | |
| Jul 7, 2026 | Class A Common Stock | SSaleDisposed | −32,550 | $42.07F4 | −$1,369,495.68 | 247,944 | Direct | |
| Jul 7, 2026 | Class A Common Stock | SSaleDisposed | −10,500 | $42.86F5 | −$450,006.9 | 237,444 | Direct | |
| Jul 7, 2026 | Class A Common Stock | SSaleDisposed | −2,200 | $43.59F6 | −$95,908.34 | 235,244 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | Class A Common Stock | MOption exerciseDisposed | −46,250 | $0.00 | $0 | 525,801 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)".
- F2
The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
- F3
The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.39 to $41.31, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.40 to $42.39, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.40 to $43.38, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.42 to $43.97, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F7
1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter.